These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30132150)

  • 1. Activin receptor-like kinase 1 is associated with immune cell infiltration and regulates CLEC14A transcription in cancer.
    Bocci M; Sjölund J; Kurzejamska E; Lindgren D; Marzouka NA; Bartoschek M; Höglund M; Pietras K
    Angiogenesis; 2019 Feb; 22(1):117-131. PubMed ID: 30132150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum/glucocorticoid-regulated kinase 1 as a novel transcriptional target of bone morphogenetic protein-ALK1 receptor signaling in vascular endothelial cells.
    Araki M; Hisamitsu T; Kinugasa-Katayama Y; Tanaka T; Harada Y; Nakao S; Hanada S; Ishii S; Fujita M; Kawamura T; Saito Y; Nishiyama K; Watanabe Y; Nakagawa O
    Angiogenesis; 2018 May; 21(2):415-423. PubMed ID: 29478089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
    de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
    Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation.
    Alsina-Sanchís E; García-Ibáñez Y; Figueiredo AM; Riera-Domingo C; Figueras A; Matias-Guiu X; Casanovas O; Botella LM; Pujana MA; Riera-Mestre A; Graupera M; Viñals F
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1216-1229. PubMed ID: 29449337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
    Hawinkels LJ; de Vinuesa AG; Paauwe M; Kruithof-de Julio M; Wiercinska E; Pardali E; Mezzanotte L; Keereweer S; Braumuller TM; Heijkants RC; Jonkers J; Löwik CW; Goumans MJ; ten Hagen TL; ten Dijke P
    Clin Cancer Res; 2016 Jan; 22(1):96-106. PubMed ID: 26373572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.
    Jonker L
    Microcirculation; 2014 Feb; 21(2):93-103. PubMed ID: 25279424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.
    Ki MK; Jeoung MH; Choi JR; Rho SS; Kwon YG; Shim H; Chung J; Hong HJ; Song BD; Lee S
    Oncogene; 2013 Nov; 32(48):5449-57. PubMed ID: 23644659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activin Receptor-Like Kinase Receptors ALK5 and ALK1 Are Both Required for TGFβ-Induced Chondrogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells.
    de Kroon LM; Narcisi R; Blaney Davidson EN; Cleary MA; van Beuningen HM; Koevoet WJ; van Osch GJ; van der Kraan PM
    PLoS One; 2015; 10(12):e0146124. PubMed ID: 26720610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.
    Hawinkels LJ; Garcia de Vinuesa A; Ten Dijke P
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1371-83. PubMed ID: 24053899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae.
    Santibanez JF; Blanco FJ; Garrido-Martin EM; Sanz-Rodriguez F; del Pozo MA; Bernabeu C
    Cardiovasc Res; 2008 Mar; 77(4):791-9. PubMed ID: 18065769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability.
    Akla N; Viallard C; Popovic N; Lora Gil C; Sapieha P; Larrivée B
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1821-1836. PubMed ID: 29880487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
    Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
    J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
    Kim TK; Park CS; Jang J; Kim MR; Na HJ; Lee K; Kim HJ; Heo K; Yoo BC; Kim YM; Lee JW; Kim SJ; Kim ES; Kim DY; Cha K; Lee TG; Lee S
    Mol Oncol; 2018 Mar; 12(3):356-372. PubMed ID: 29316206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
    Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
    Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
    Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
    Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours.
    Robinson J; Whitworth K; Jinks E; Nagy Z; Bicknell R; Lee SP
    J Pathol Clin Res; 2020 Oct; 6(4):308-319. PubMed ID: 32696621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway.
    Fernández-L A; Sanz-Rodriguez F; Blanco FJ; Bernabéu C; Botella LM
    Clin Med Res; 2006 Mar; 4(1):66-78. PubMed ID: 16595794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of a regulatory region of activin receptor-like kinase 1 gene sufficient for arterial endothelium-specific expression.
    Seki T; Hong KH; Yun J; Kim SJ; Oh SP
    Circ Res; 2004 Apr; 94(8):e72-7. PubMed ID: 15059937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling.
    Goumans MJ; Valdimarsdottir G; Itoh S; Lebrin F; Larsson J; Mummery C; Karlsson S; ten Dijke P
    Mol Cell; 2003 Oct; 12(4):817-28. PubMed ID: 14580334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.